ISMIVS Newsletter 2026 March & April Newsletter ISMIVS

ISMIVS Newsletter 2026 March & April

Newsletter 2026 March & April
2026年3&4月简报

About Us 国际微无创医学会简介

The International Society of Minimally Invasive and Virtual Surgery (ISMIVS, previously known as International Society of Minimally Invasive and Noninvasive Medicine) was founded in July 2013 at the gala of the 1st Yangtze International Summit of Minimally Invasive and Noninvasive Medicine in Chongqing, China. ISMIVS envisions to accelerating the progress in minimally invasive and noninvasive medicine by promoting research, education, communication, and international collaboration.
国际微无创医学会（ISMIVS）是在 2013 年 7 月在中国重庆召开的第一届国际微无创医学长江高峰论坛上宣布成立的，旨在通过学术研究、教育、交流以及国际合作加快微无创医学的发展。

Become a member 注册成为会员 >

Ideas about Young ISMIVS 医路青春专访栏目

Ideas about Young ISMIVS
医路青春专访栏目

In July 2023, the Young ISMIVS Committee was formally established in order to respond to the development trend of minimally invasive and noninvasive medicine, and further consolidate the core group of young physicians.
为顺应微无创医学发展的趋势，进一步凝聚中青年微无创医学骨干的力量，推动微无创医学的发展。2023年7月，国际微无创医学会“青年委员会”（以下简称“青委会”）正式成立。
As the youth force of the new era in the field of minimally invasive and noninvasive medicine, the Young ISMIVS Committee carries the important mission of enlightening medical innovation and leading the development of this field. It will become a solid pillar to promote the breakthroughs in minimally invasive and noninvasive medicine to new heights through its unique vitality and profound deposits.
青委会作为微无创领域新时代的青春力量，承载着启迪医学创新、引领微无创技术发展的重要使命，将凭借其独特的创新活力和深厚的专业积淀，成为推动微无创领域不断突破、迈向新高峰的坚实砥柱。
In medicine, a group of passionate young physicians, who harbor the love and persistence for minimal invasiveness and non-invasiveness, keep exploring and moving forward. They are the members of the Young ISMIVS Committee, who contribute to the development of this field with their enthusiasm and wisdom.
在医学的广阔天地里，这样一群热血的青年医者，他们怀揣着对微无创医学的热爱与执着，不断探索、不断前行。他们，正是青委会的成员，他们以青春的热情与智慧，为微无创医学的发展贡献着自己的力量。
In conjunction with Da Yi Wei Ke, we are now introducing the first interview show – Ideas about Young ISMIVS. Let's get closer to this group of young doctors, listen to their stories on the path of minimally invasive and non-invasive medicine, feel their passion and persistence, and witness the bright future together.
国际微无创医学会青年委员会联合大医微课策划出品，首档人物专访节目《医路青春》正在播出。让我们走近这群青年医者，聆听他们在微无创路上的成长故事，感受他们的热情与执着，共同见证微无创医学的辉煌未来。

Ideas about Young ISMIVS with:
本期嘉宾：

Yang Li
Chief Physician
The Third Affiliated Hospital of Zhengzhou University
杨立
主任医师
郑州大学第三附属医院

-Standing Committee Member of the Young ISMIVS Committeee
-Director of the Zhengzhou Key Laboratory for the Prevention and Treatment of Endometrial Diseases
-Deputy Director of the Zhengzhou Key Laboratory for Cervical Cancer
-国际微无创医学会青年委员会常务委员
-郑州市子宫内膜疾病防治重点实验室主任
-郑州市宫颈癌重点实验室副主任

Watch the interview:

https://youtu.be/fy9X3U1BEYY?si=pWq5VZMYR7Ocshy_

观看本期采访：

https://mp.weixin.qq.com/s/ECqJnoJcXX3ZpzdsYgdrEg

News 新闻

Parallel Session of ISMINIM 2025: Minimally Invasive and Non-invasive Approaches for Breast Disease Management
2025微无创医学长江论坛分会场精彩速递：乳腺疾病的微无创治疗

This panel session brought together leading experts in the field of minimally invasive and non-invasive treatments for breast diseases in China. Through keynote presentations and academic discussions, participants engaged in in-depth exploration of the application and innovation of cutting-edge technologies, such as focused ultrasound, in the treatment of breast diseases.
本次分论坛汇聚了国内乳腺疾病微无创治疗领域的顶尖专家，通过专题报告和学术讨论，深入探讨了聚焦超声等前沿技术在乳腺疾病治疗中的应用与创新。

The session was moderated by Xiao Lixin from Hunan Provincial Maternal and Child Health Hospital; Tan Jiankun, Deputy Party Secretary and Director of Guigang Maternal and Child Health Hospital in Guangxi; Wang Mengyuan, Director of the Breast Center at Chongqing University Affiliated Three Gorges Hospital; and Chen Bo, Director of the Thyroid and Breast Surgery Department at Hubei Provincial Maternal and Child Health Hospital.
湖南省妇幼保健院肖立新、广西贵港市妇幼保健院党委副书记/院长谭健坤、重庆大学附属三峡医院乳腺中心主任王梦远、湖北省妇幼保健院甲状腺乳腺外科主任陈波等人担任主持。
Professor Yang Hongwei, Party Secretary of Suining Central Hospital, began by presenting “The Application of Focused Ultrasound in the Treatment of Breast Diseases.” He provided a systematic overview of the technology’s principles, clinical advantages, and latest research findings, emphasizing its value in delivering precise treatment while preserving breast tissue function.
遂宁市中心医院党委书记杨宏伟教授首先分享了《聚焦超声在乳腺疾病治疗中的应用》，系统介绍了该技术的原理、临床优势及最新研究成果，强调了其在保留乳腺组织功能的同时实现精准治疗的价值。
Professor Wang Haixing, Director of the HIFU Center at Shijiazhuang Maternal and Child Health Hospital, delivered a presentation titled “Focused Ultrasound Therapy for Granulomatous Mastitis.” Drawing on clinical cases, he elaborated in detail on the therapeutic efficacy and key operational points of focused ultrasound for this complex condition, providing important guidance for clinical practice.
石家庄市妇产医院海扶中心主任王海兴教授以《肉芽肿性乳腺炎的聚焦超声治疗》为题，结合临床案例，详细阐述了聚焦超声对这一疑难病症的治疗效果及操作要点，为临床实践提供了重要参考。
Professor Zhang Anqin, Director of the Breast Surgery Department at the Guangdong Provincial Maternal and Child Health Hospital affiliated with Southern University of Science and Technology, delivered a presentation titled “Exploration of Minimally Invasive and Non-Invasive Treatments Under the Concept of R0 Resection for Breast Cancer.” She proposed an innovative approach that aims to reduce patient trauma and improve quality of life through minimally invasive and non-invasive techniques, while ensuring radical tumor resection.
南方科技大学附属广东省妇幼保健院乳腺科主任张安秦教授发表了题为《乳腺癌 R0 切除理念下微无创治疗探索》的演讲，提出在保证肿瘤根治性切除的前提下，通过微无创技术减少患者创伤、改善生活质量的创新理念。
Professor Li Meifang, Deputy Director of the Breast Disease Diagnosis and Treatment Center at the First Affiliated Hospital of Gannan Medical College, approached the topic from the perspective of “Optimizing Treatment Strategies for Benign Breast Tumors.” Drawing on evidence-based medicine, she discussed how to develop personalized treatment plans for patients.
赣南医学院第一附属医院乳腺疾病诊疗中心副主任李梅芳教授则从《乳腺良性肿瘤治疗策略的优化》角度出发，结合循证医学证据，探讨了如何为患者制定个性化治疗方案。
Experts including Zhu Jing, Deputy Director of the Breast Department at Foshan Maternal and Child Health Hospital; Shen Haoyuan from Xiaogan Hospital Affiliated to Wuhan University of Science and Technology; and Liang Mengdi from the Breast Center at Jiangsu Provincial People’s Hospital shared their perspectives on topics such as the standardized application of minimally invasive techniques and multidisciplinary collaboration models, offering new insights for clinical practice.
佛山市妇幼保健院乳腺科副主任朱婧、武汉科技大学附属孝感医院沈浩元、江苏省人民医院乳腺中心梁梦迪等专家就微无创技术的规范化应用、多学科协作模式等议题各抒己见，为临床实践提供了新思路。

Watch the playback of the Summit:

https://www.youtube.com/playlist?list=PLWbjlVbxcLm3p9sE4xg3Z8YdcvZ4xOuYj

观看会议回放：

https://live.dayiweike.com/video/huikan/1980?m=jin

New Perspective in Focused Ultrasound 聚焦超声新视角

Analysis of Pregnancy Outcomes and Influencing Factors in Patients with Uterine Fibroids after High-intensity Focused Ultrasound Ablation
高强度聚焦超声消融术后子宫肌瘤患者妊娠结局及其影响因素分析

The objective of this study is to analyze factors influencing pregnancy outcomes in patients with uterine fibroids after high-intensity focused ultrasound (HIFU) treatment.

本研究旨在分析高强度聚焦超声（HIFU）治疗后子宫肌瘤患者妊娠结局的影响因素。

Patients with uterine fibroids who wished to have children underwent HIFU treatment at Chongqing Haifu Hospital from April 2011 to May 2024 were retrospectively reviewed. HIFU treatment results were evaluated using magnetic resonance imaging, and the postoperative pregnancy outcomes were evaluated.

对 2011 年 4 月至 2024 年 5 月期间在重庆海扶医院接受HIFU治疗且有生育意愿的子宫肌瘤患者进行了回顾性分析。通过磁共振成像评估HIFU治疗效果，并评估术后妊娠结局。

302 out of 748 (40.4%) patients became pregnant after HIFU, including 88.1% (273/310) in natural and 11.9% (37/310) in assisted reproduction. At the end of follow-up, 273 patients had 281 successful deliveries. No patient had a uterine rupture during pregnancy or delivery after HIFU. Patients with multiple fibroids had a lower probability of conception compared to those with a single fibroid (odds ratio [OR] >1, P < 0.05). A larger NPV ratio was associated with a higher likelihood of pregnancy (OR > 1, P < 0.05). Submucosal fibroids were an independent risk factor for pregnancy compared to subserosal fibroids (OR > 1, P < 0.05). In contrast, intramural or mixed-type fibroids were independent protective factors for pregnancy compared to submucosal fibroids (OR < 1, P < 0.05). A significant difference in NPV ratio and number of fibroids was also observed between patients in the delivery group and the miscarriage group (P < 0.05).

748 名患者中有 302 名（40.4%）在 HIFU 治疗后成功妊娠，其中自然受孕88.1%（273/310），辅助生殖占 11.9%（37/310）。随访结束时，273 名患者共分娩 281例。接受 HIFU 治疗后，没有患者在怀孕或分娩期间发生子宫破裂。与单发子宫肌瘤患者相比，多发子宫肌瘤患者的受孕概率较低（比值比 [OR] >1，P < 0.05）。负预测值（NPV）比率越高，妊娠可能性越大（OR > 1，P < 0.05）。与浆膜下肌瘤相比，黏膜下肌瘤是妊娠的独立风险因素（OR > 1，P < 0.05）。相反，与黏膜下肌瘤相比，肌壁间或混合型肌瘤是妊娠的独立保护因素（OR < 1，P < 0.05）。分娩组与流产组患者在阴性预测值比及肌瘤数量方面也存在显著差异（P < 0.05）。

HIFU treatment is safe and effective for patients with uterine fibroids who wish to have a child. Older age, multiple fibroids, submucosal fibroids, and low NPV have negative effects on pregnancy.

对于希望生育的子宫肌瘤患者而言，HIFU 治疗是安全且有效的。高龄、多发性肌瘤、黏膜下肌瘤以及较低的阴性预测值（NPV）都会对怀孕产生负面影响。

Tech Update in Gynaecological Endoscopy 妇科腔镜技术最新进展

Endometriosis and Chronic Endometritis: Shared Mechanisms, Diagnostic Challenges, and Clinical Implications in Infertility
子宫内膜异位症与慢性子宫内膜炎：共同机制、诊断挑战及对不孕症的临床意义

Endometriosis (EM) and chronic endometritis (CE) are both implicated in female infertility, yet the relationship between them remains incompletely understood. In this narrative review, we synthesize non-systematically selected clinical and mechanistic evidence on EM-CE coexistence, with emphasis on infertility-related settings and diagnostic uncertainty. Available studies, largely from selected infertility cohorts, suggest that CE is identified more often in women with EM, raising the possibility that their coexistence reflects a biologically meaningful association rather than incidental overlap.
子宫内膜异位症（EM）和慢性子宫内膜炎（CE）均与女性不孕有关，但两者之间的关系尚未完全明确。在本篇叙述性综述中，我们综合了关于 EM 与 CE 共存的非系统性筛选临床及机制证据，重点关注与不孕症相关的临床情境及诊断不确定性。现有研究（主要来自选定的不孕症队列）表明，在 EM 患者中更常发现 CE，这提示两者的共存可能反映了具有生物学意义的关联，而非偶然的重叠。
The two conditions share several abnormalities that may impair reproduction, including persistent inflammation, immune dysregulation, altered cytokine and chemokine signaling, impaired macrophage and natural killer cell function, progesterone resistance, and reduced endometrial receptivity. In addition to the pelvic anatomical distortion and ovarian dysfunction associated with EM, CE may further compromise implantation by impairing decidualization, displacing the window of implantation, and disrupting the local endometrial microenvironment. Both conditions also remain diagnostically challenging.
这两种疾病存在若干共同的异常表现，可能影响生殖功能，包括持续性炎症、免疫紊乱、细胞因子和趋化因子信号传导异常、巨噬细胞和自然杀伤细胞功能受损、孕酮抵抗以及子宫内膜容受性降低。除了与 EM 相关的盆腔解剖结构畸形和卵巢功能障碍外，CE 还可能通过阻碍蜕膜化、改变着床窗口期以及破坏局部子宫内膜微环境，进一步影响胚胎着床。这两种病症在诊断上也仍然具有挑战性。
EM is most reliably confirmed by laparoscopy with histologic verification, whereas CE is generally diagnosed by hysteroscopy and endometrial biopsy demonstrating plasma cells. For CE in particular, the lack of standardized diagnostic criteria and uniform CD138 thresholds continues to limit diagnostic consistency.
腹腔镜检查结合病理学验证是确诊 EM 最可靠的方法，而 CE 通常通过宫腔镜检查和子宫内膜活检（显示浆细胞）进行诊断。特别是对于 CE，由于缺乏标准化诊断标准和统一的 CD138 阈值，诊断的一致性仍受到限制。
Emerging imaging techniques, molecular biomarkers, microbiota-based approaches, and artificial intelligence-assisted models remain investigational or adjunctive rather than established tools for routine integrated assessment.
新兴的影像学技术、分子生物标志物、基于微生物组的检测方法以及人工智能辅助模型，目前仍处于研究阶段或仅作为辅助手段，尚未成为常规综合评估的成熟工具。
Taken together, the current evidence is hypothesis-generating and supports selective, phenotype-driven consideration of coexisting EM and CE in infertility care rather than routine dual invasive evaluation.
综合来看，现有证据有助于提出新假说，并支持在不孕症诊疗中针对并存的子宫内膜异位症（EM）和子宫内膜增生（CE）采取有针对性的、以表型为导向的评估方案，而非常规进行双重侵入性检查。
Further studies are required to clarify the mechanisms linking these conditions, define their combined reproductive impact, and determine whether integrated diagnostic and therapeutic strategies can improve fertility outcomes.
需要进一步开展研究，以阐明这些疾病之间的关联机制，明确其对生殖功能的综合影响，并确定综合诊断和治疗策略能否改善生育结局。